Evidence map›Paper›PMID 40247170›Full record

ArticleBMC cardiovascular disorders2025

VEGF-A cis-located SNPs on human chromosome 6 associated with VEGF-A plasma levels and survival in a coronary disease cohort.

J C Meza-Alvarado, A P Pilbrow, C M Frampton, V A Cameron, A M Richards, R W Troughton, R N Doughty, R A Page, B Mallard, C Bromhead and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

J C Meza-AlvaradoSchool of Health Sciences, School of Health Sciences, Massey University, Wellington, New Zealand.
A P PilbrowThe Christchurch Heart Institute, University of Otago, Christchurch, New Zealand.
C M FramptonThe Christchurch Heart Institute, University of Otago, Christchurch, New Zealand.
V A CameronThe Christchurch Heart Institute, University of Otago, Christchurch, New Zealand.
A M RichardsThe Christchurch Heart Institute, University of Otago, Christchurch, New Zealand.
R W TroughtonThe Christchurch Heart Institute, University of Otago, Christchurch, New Zealand.
R N DoughtyFaculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
R A PageSchool of Health Sciences, School of Health Sciences, Massey University, Wellington, New Zealand.
B MallardSchool of Health Sciences, School of Health Sciences, Massey University, Wellington, New Zealand.
C BromheadSchool of Health Sciences, School of Health Sciences, Massey University, Wellington, New Zealand.
B R PalmerSchool of Health Sciences, School of Health Sciences, Massey University, Wellington, New Zealand. b.palmer@massey.ac.nz.

Funding

Health Research Council of New Zealand HRC 02/152Heart Foundation of New Zealand HFNZ1936Maurice and Phyllis Paykel Trust 221105
6 · The paper itself

Abstract

backgroundCardiovascular disease (CVD) is the leading cause of death worldwide. Risk stratification of CVD patients may be improved by predictive biomarkers, including genetic markers. Elevated circulating vascular endothelial growth factor A (VEGF-A) levels have been linked to CVD development. We explored whether single nucleotide polymorphisms (SNPs) at the VEGFA locus on human chromosome 6 were associated with VEGF-A levels and clinical outcomes in established CVD. VEGF-A levels were compared between coronary heart disease patients and heart healthy controls.

methodsImputed genotypes of 30 SNPs from the VEGFA region for 1935 patients from the Coronary Disease Cohort Study (CDCS) and 1183 individuals from the Canterbury Healthy Volunteers Study (HVOL) were analysed for associations with cardiometabolic parameters. Association with clinical endpoints was assessed using Kaplan-Meier analysis and multivariate regression models. To validate the findings from imputed data, DNA samples of 2027 CDCS patients and 227 HVOL participants were manually genotyped for variants rs6921438 and rs7767396. Baseline plasma VEGF-A assayed by ELISA in 227 HVOL participants was compared with levels in 549 CDCS patients.

resultsManual genotyping showed rs6921438 AA and rs7767396 GG genotype groups had lower VEGF-A levels at baseline (CDCS: rs6921438 AA (27.7 pg/mL), AG (43.3 pg/mL), GG (63.2 pg/mL), p = 4.49 × 10

conclusionsVariants rs6921438 and rs7767396 are associated with plasma VEGF-A levels. Both SNPs and VEGF-A may be useful in prognosis for HF after acute coronary events.

Indexed as

Chromosomes, Human, Pair 6Coronary DiseasePolymorphism, Single NucleotideVascular Endothelial Growth Factor AAgedBiomarkersCase-Control StudiesFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHumansMaleMiddle AgedPhenotypePrognosisRisk AssessmentBiomarkersVascular Endothelial Growth Factor AVEGFA protein, humanOutcomePrognosisrs6921438rs7767396Single nucleotide polymorphismVascular endothelial growth factor

Identifiers

PMID40247170
PMCPMC12004769

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.